Accessibility Menu
Patrys logo

Patrys(ASX) PAB

Market CapA$21.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-99%
5 Year-95%
1 Year+7%
1 Month-18%
A$0.03
-3.13%
-0.00Today
Patrys last closing stock price
MetricPriceDate
Last closeAUD 0.032026-08-13
Patrys stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.03%AUD 0.032026-08-06
1 month-17.95%AUD 0.042026-07-14
3 month+3.23%AUD 0.032026-05-15
Year to date+14.29%AUD 0.032025-12-31
1 year+6.67%AUD 0.032025-08-13
3 year-77.54%AUD 0.142023-08-14
5 year-94.8%AUD 0.622021-08-13
Since inception-99.4%AUD 5.302007-07-13

Patrys Financials at a Glance

Market Cap

A$21.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.55M

Net Income (TTM)

-A$7.62M

EPS (TTM)

-A$0.02

P/E Ratio

-1.69

Dividend

A$0.00

Beta (Volatility)

-0.30 (Low)

Price

A$0.03

Volume

108,027

Open

A$0.03

Previous Close

A$0.03

Daily Range

A$0.03 - A$0.03

52-Week Range

A$0.02 - A$0.05

Estimated Earnings Date

Feb 19, 2026

PAB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Patrys

Patrys Limited is a biotechnology company based in Melbourne, Australia, focused on developing advanced antibody technologies for cancer treatment. The company is known for its innovative therapeutic candidates, including Deoxymab 3E10 and PAT-DX1, which target cancer cells effectively.

Products and Services
  • Deoxymab 3E10: A DNA damage-repair antibody for cancer therapy
  • PAT-DX1: An antibody fragment targeting primary and secondary brain cancers
  • PAT-DX3: A full-sized antibody under evaluation for its pharmacokinetic profile
Growth Outlook
  • Pipeline advancements indicate potential for significant market impact
  • Focus on targeted therapies aligns with industry trends towards precision medicine
  • Strong research and development efforts support future product launches
Financial Highlights
  • Recent quarterly revenue of AUD 0, reflecting ongoing development phase
  • Cash and cash equivalents increased to AUD 1,903,841 in the latest quarter
  • Current ratio of 3.80 indicates strong liquidity position
Patrys Limited is positioned in the healthcare sector, specifically within biotechnology, where it aims to address unmet medical needs in cancer treatment. The company's innovative approach to antibody technology, particularly in targeting DNA damage repair mechanisms, sets it apart in a competitive landscape. With a focus on research and development, Patrys is actively working to advance its product pipeline, which includes promising candidates for treating various forms of cancer. The financial data reflects a company in the development stage, with no revenue reported in the latest quarter, but a solid cash position that supports ongoing research activities. The current ratio suggests that Patrys has sufficient liquidity to meet its short-term obligations, which is crucial for sustaining operations during the development phase. Overall, Patrys Limited represents an intriguing opportunity for investors interested in the biotechnology sector, particularly those focused on innovative cancer therapies. The company's commitment to advancing its pipeline and addressing significant medical challenges could lead to substantial growth in the future.
AI Generated • Jul 24, 2026

Industry

Biotechnology

CEO

James A. Campbell, PhD, MBA

Headquarters

Nedlands, WA 6009, AU

PAB Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-4295.26%

Net Income Margin

-4602.61%

Return on Equity

-406.05%

Return on Capital

-369.72%

Return on Assets

-223.16%

Earnings Yield

-59.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$21.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

674.85M

Volume

108.03K

Avg. Volume

850.56K

Financials (TTM)

Gross Profit

A$1.55M

Operating Income

-A$7.32M

EBITDA

-A$7.25M

Operating Cash Flow

-A$4.65M

Capital Expenditure

-A$3.24K

Free Cash Flow

-A$4.66M

Cash & ST Invst.

A$1.90M

Total Debt

A$0.00

Patrys Performance Analysis

Patrys annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 27,500N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Patrys sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-308.3%
Q22024-12-310.8%
Q42025-06-30-86.6%
Q22025-12-31-100.0%
Patrys annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.04N/A
20232023-06-30AUD -0.04-0.5%
20242024-06-30AUD -0.02-50.0%
20252025-06-30AUD -0.02-15.3%
Patrys sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3020.0%
Q22024-12-3112.5%
Q42025-06-3014.3%
Q22025-12-31-1783.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

A$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

A$21.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.44M

N/A

Employees

15

N/A

Net Income

-A$3.02M

-54.8%

EBITDA

-A$3.02M

-56.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$1.90M

-57.3%

Total Debt

A$0.00

N/A

Accounts Receivable

A$54.71K

-91.6%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-2.23%

N/A

Return on Invested Capital

-2.83%

N/A

Free Cash Flow

-A$661.56K

-264.3%

Operating Cash Flow

-A$661.56K

-264.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BTC.AXBTC Health Limited
A$0.06+0.00%
AGH.AXAlthea Group Holdings Limited
A$0.02-4.76%
IME.AXImExHS Limited
A$0.31-3.13%
MDR.AXMedAdvisor Limited
A$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About PAB

What is the current price of Patrys?

Patrys is trading at A$0.03 per share.

What is the 52-week range for Patrys?

Over the past 52 weeks, Patrys has traded between A$0.02 and A$0.05.

How much debt does Patrys have?

As of the most recent reporting period, Patrys reported total debt of A$0.00.

How much cash does Patrys have on hand?

Patrys reported A$742.44K in cash and cash equivalents in its most recent financial results.

What is Patrys’s dividend yield?

Patrys does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.